Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Prediction: This Could Be This Company's Next Billion-Dollar Product | Nasdaq
Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
The promising future of insulin therapy in diabetes mellitus | American Journal of Physiology-Endocrinology and Metabolism
Novo Nordisk once-weekly insulin icodec beats Tresiba, matches Sanofi's Lantus in trials | Seeking Alpha
Novo Nordisk tees up phase 3 trial for once-weekly insulin | Fierce Biotech
Novo Nordisk Once-Weekly Insulin Comparable to Daily Injections - Type 2 Nation
Novo Nordisk 2022: Expanding capabilities – PharmaLive
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduct
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Novo Nordisk achieve headline results with icodec insulin | pharmaphorum
